Open Access

Science

, volume 371 , issue 6532 , pages 926-931

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

Kris M White ^{1, 2}

Romel Rosales ^{1, 2}

Soner Yildiz ^{1, 2}

Thomas Kehrer ^{1, 2}

Lisa Miorin ^{1, 2}

E. Moreno ^{1, 2}

Sonia Jangra ^{1, 2}

Melissa B Uccellini ^{1, 2}

Raveen Rathnasinghe ^{1, 2}

Lynda Coughlan ³

Carles Martínez-Romero ^{1, 2}

Jyoti Batra ^{4, 5, 6, 7}

Ajda Rojc ^{4, 5, 6, 7}

Mehdi Bouhaddou ^{4, 5, 6, 7}

Jacqueline M Fabius ^{4, 6}

Kirsten Obernier ^{4, 5, 6, 7}

Marion Dejosez ⁸

María José Guillén ⁹

Alejandro Losada ⁹

Pablo Avilés ⁹

M. Schotsaert ^{1, 2}

Thomas P. Zwaka ⁸

Marco Vignuzzi ¹⁰

Kevan M. Shokat ^{4, 6, 7, 11}

Nevan J. Krogan ^{1, 4, 5, 6, 7}

Adolfo García-Sastre ^{1, 2, 12, 13}

Hide authors affiliations Show authors affiliations: 13 affiliations

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. |

Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. |

Department of Microbiology and Immunology and Center for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, USA. |

⁴

Quantitative Biosciences Institute (QBI), University of California, San Francisco, CA 94158, USA. |

⁵

J. David Gladstone Institutes, San Francisco, CA 94158, USA. |

⁶

QBI Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA. |

⁷

Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA. |

⁸

Huffington Foundation Center for Cell-Based Research in Parkinson’s Disease, Department of Cell, Developmental, and Regenerative Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. |

⁹

Research and Development Department, PharmaMar, 28770 Colmenar Viejo, Madrid, Spain. |

¹⁰

Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 75724 Paris Cedex 15, France. |

¹¹

Howard Hughes Medical Institute, University of California, San Francisco, CA 94143, USA.

University of California, San Francisco

Howard Hughes Medical Institute

¹²

Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. |

¹³

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. |

Publication type: Journal Article

Publication date: 2021-02-26

American Association for the Advancement of Science (AAAS)

Science

scimago Q1

wos Q1

SJR: 10.416

CiteScore: 48.4

Impact factor: 45.8

ISSN: 00368075, 10959203

DOI: 10.1126/science.abf4058

Copy DOI

PubMed ID: 33495306

Multidisciplinary

Abstract

Hurting the virus by targeting the host

Many host proteins play a role in the life cycle of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and some are required for viral replication and translation. There are efforts toward finding drugs that target viral proteins, but a complementary approach is to target these required host proteins. White et al. explored the antiviral activity of the cyclic depsipeptide drug plitidepsin, which targets the hosts cell's translational machinery (see the Perspective by Wong and Damania). The authors show that in cells, the drug is substantially more potent than remdesivir against SARS-CoV-2, with limited cellular toxicity. Prophylactic treatment protected mice against SARS-CoV-2 infection, so further investigation of plitidepsin as a therapeutic is warranted.

Science , this issue p. 926 ; see also p. 884

Found

1 citation

Perveen Shagufta

165 publications, 2 463 citations, 13 reviews

h-index: 24

King Saud University

University of the Punjab

Government College University, Faisalabad

1 citation

Wake Rachel

63 publications, 7 497 citations, 5 reviews

h-index: 33

St George's, University of London

1 citation

LUCA MIHAELA

🥼 🤝

97 publications, 640 citations

h-index: 13

Research interests

Artificial intelligence

Fuzzy Systems

Image Processing

Machine learning

1 citation

Falco Antonio

79 publications, 645 citations, 62 reviews

h-index: 13

CEU Cardinal Herrera University

Research interests

Computational mathematics

Top-30

Journals

	2 4 6 8 10 12
Marine Drugs	Marine Drugs, 11, 3.77% Marine Drugs 11 publications, 3.77%
bioRxiv	bioRxiv, 8, 2.74% bioRxiv 8 publications, 2.74%
Molecules	Molecules, 7, 2.4% Molecules 7 publications, 2.4%
Journal of Natural Products	Journal of Natural Products, 7, 2.4% Journal of Natural Products 7 publications, 2.4%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 6, 2.05% International Journal of Molecular Sciences 6 publications, 2.05%
Frontiers in Immunology	Frontiers in Immunology, 6, 2.05% Frontiers in Immunology 6 publications, 2.05%
Viruses	Viruses, 5, 1.71% Viruses 5 publications, 1.71%
Nature Communications	Nature Communications, 5, 1.71% Nature Communications 5 publications, 1.71%
Cell	Cell, 5, 1.71% Cell 5 publications, 1.71%
mBio	mBio, 4, 1.37% mBio 4 publications, 1.37%
Nature	Nature, 4, 1.37% Nature 4 publications, 1.37%
Antiviral Research	Antiviral Research, 4, 1.37% Antiviral Research 4 publications, 1.37%
International Journal of Biological Macromolecules	International Journal of Biological Macromolecules, 4, 1.37% International Journal of Biological Macromolecules 4 publications, 1.37%
Pharmaceuticals	Pharmaceuticals, 3, 1.03% Pharmaceuticals 3 publications, 1.03%
Frontiers in Pharmacology	Frontiers in Pharmacology, 3, 1.03% Frontiers in Pharmacology 3 publications, 1.03%
Antimicrobial Agents and Chemotherapy	Antimicrobial Agents and Chemotherapy, 3, 1.03% Antimicrobial Agents and Chemotherapy 3 publications, 1.03%
Briefings in Bioinformatics	Briefings in Bioinformatics, 3, 1.03% Briefings in Bioinformatics 3 publications, 1.03%
Science	Science, 2, 0.68% Science 2 publications, 0.68%
Scientific Reports	Scientific Reports, 2, 0.68% Scientific Reports 2 publications, 0.68%
Nature Microbiology	Nature Microbiology, 2, 0.68% Nature Microbiology 2 publications, 0.68%
Microorganisms	Microorganisms, 2, 0.68% Microorganisms 2 publications, 0.68%
Pharmaceutics	Pharmaceutics, 2, 0.68% Pharmaceutics 2 publications, 0.68%
Frontiers in Molecular Biosciences	Frontiers in Molecular Biosciences, 2, 0.68% Frontiers in Molecular Biosciences 2 publications, 0.68%
Frontiers in Marine Science	Frontiers in Marine Science, 2, 0.68% Frontiers in Marine Science 2 publications, 0.68%
Amino Acids	Amino Acids, 2, 0.68% Amino Acids 2 publications, 0.68%
npj Digital Medicine	npj Digital Medicine, 2, 0.68% npj Digital Medicine 2 publications, 0.68%
Communications Biology	Communications Biology, 2, 0.68% Communications Biology 2 publications, 0.68%
Bioorganic Chemistry	Bioorganic Chemistry, 2, 0.68% Bioorganic Chemistry 2 publications, 0.68%
Computers in Biology and Medicine	Computers in Biology and Medicine, 2, 0.68% Computers in Biology and Medicine 2 publications, 0.68%
	2 4 6 8 10 12

Publishers

	10 20 30 40 50 60
Elsevier	Elsevier, 59, 20.21% Elsevier 59 publications, 20.21%
MDPI	MDPI, 43, 14.73% MDPI 43 publications, 14.73%
Springer Nature	Springer Nature, 41, 14.04% Springer Nature 41 publications, 14.04%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 31, 10.62% Cold Spring Harbor Laboratory 31 publications, 10.62%
Frontiers Media S.A.	Frontiers Media S.A., 18, 6.16% Frontiers Media S.A. 18 publications, 6.16%
American Chemical Society (ACS)	American Chemical Society (ACS), 17, 5.82% American Chemical Society (ACS) 17 publications, 5.82%
Wiley	Wiley, 17, 5.82% Wiley 17 publications, 5.82%
American Society for Microbiology	American Society for Microbiology, 13, 4.45% American Society for Microbiology 13 publications, 4.45%
Oxford University Press	Oxford University Press, 9, 3.08% Oxford University Press 9 publications, 3.08%
Taylor & Francis	Taylor & Francis, 6, 2.05% Taylor & Francis 6 publications, 2.05%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 4, 1.37% Royal Society of Chemistry (RSC) 4 publications, 1.37%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 4, 1.37% Bentham Science Publishers Ltd. 4 publications, 1.37%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 2, 0.68% American Association for the Advancement of Science (AAAS) 2 publications, 0.68%
Rockefeller University Press	Rockefeller University Press, 2, 0.68% Rockefeller University Press 2 publications, 0.68%
IGI Global	IGI Global, 2, 0.68% IGI Global 2 publications, 0.68%
Canadian Science Publishing	Canadian Science Publishing, 1, 0.34% Canadian Science Publishing 1 publication, 0.34%
Microbiology Society	Microbiology Society, 1, 0.34% Microbiology Society 1 publication, 0.34%
Spandidos Publications	Spandidos Publications, 1, 0.34% Spandidos Publications 1 publication, 0.34%
Baishideng Publishing Group	Baishideng Publishing Group, 1, 0.34% Baishideng Publishing Group 1 publication, 0.34%
SAGE	SAGE, 1, 0.34% SAGE 1 publication, 0.34%
Huazhong University of Science and Technology	Huazhong University of Science and Technology, 1, 0.34% Huazhong University of Science and Technology 1 publication, 0.34%
Pensoft Publishers	Pensoft Publishers, 1, 0.34% Pensoft Publishers 1 publication, 0.34%
Korean Society for Microbiology and Biotechnology	Korean Society for Microbiology and Biotechnology, 1, 0.34% Korean Society for Microbiology and Biotechnology 1 publication, 0.34%
The Japan Institute of Heterocyclic Chemistry	The Japan Institute of Heterocyclic Chemistry, 1, 0.34% The Japan Institute of Heterocyclic Chemistry 1 publication, 0.34%
Hindawi Limited	Hindawi Limited, 1, 0.34% Hindawi Limited 1 publication, 0.34%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 1, 0.34% American Association for Cancer Research (AACR) 1 publication, 0.34%
eLife Sciences Publications	eLife Sciences Publications, 1, 0.34% eLife Sciences Publications 1 publication, 0.34%
Japanese Society of Fisheries Science	Japanese Society of Fisheries Science, 1, 0.34% Japanese Society of Fisheries Science 1 publication, 0.34%
Mark Allen Group	Mark Allen Group, 1, 0.34% Mark Allen Group 1 publication, 0.34%
	10 20 30 40 50 60

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

PDF

Metrics

292

Cite this

GOST |

Cite this

GOST Copy

White K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A // Science. 2021. Vol. 371. No. 6532. pp. 926-931.

GOST all authors (up to 50) Copy

White K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A // Science. 2021. Vol. 371. No. 6532. pp. 926-931.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1126/science.abf4058

UR - https://doi.org/10.1126/science.abf4058

TI - Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

T2 - Science

AU - White, Kris M

AU - Rosales, Romel

AU - Yildiz, Soner

AU - Kehrer, Thomas

AU - Miorin, Lisa

AU - Moreno, E.

AU - Jangra, Sonia

AU - Uccellini, Melissa B

AU - Rathnasinghe, Raveen

AU - Coughlan, Lynda

AU - Martínez-Romero, Carles

AU - Batra, Jyoti

AU - Rojc, Ajda

AU - Bouhaddou, Mehdi

AU - Fabius, Jacqueline M

AU - Obernier, Kirsten

AU - Dejosez, Marion

AU - Guillén, María José

AU - Losada, Alejandro

AU - Avilés, Pablo

AU - Schotsaert, M.

AU - Zwaka, Thomas P.

AU - Vignuzzi, Marco

AU - Shokat, Kevan M.

AU - Krogan, Nevan J.

AU - García-Sastre, Adolfo

PY - 2021

DA - 2021/02/26

PB - American Association for the Advancement of Science (AAAS)

SP - 926-931

IS - 6532

VL - 371

PMID - 33495306

SN - 0036-8075

SN - 1095-9203

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2021_White,

author = {Kris M White and Romel Rosales and Soner Yildiz and Thomas Kehrer and Lisa Miorin and E. Moreno and Sonia Jangra and Melissa B Uccellini and Raveen Rathnasinghe and Lynda Coughlan and Carles Martínez-Romero and Jyoti Batra and Ajda Rojc and Mehdi Bouhaddou and Jacqueline M Fabius and Kirsten Obernier and Marion Dejosez and María José Guillén and Alejandro Losada and Pablo Avilés and M. Schotsaert and Thomas P. Zwaka and Marco Vignuzzi and Kevan M. Shokat and Nevan J. Krogan and Adolfo García-Sastre and others},

title = {Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A},

journal = {Science},

year = {2021},

volume = {371},

publisher = {American Association for the Advancement of Science (AAAS)},

month = {feb},

url = {https://doi.org/10.1126/science.abf4058},

number = {6532},

pages = {926--931},

doi = {10.1126/science.abf4058}

}

MLA

Cite this

MLA Copy

White, Kris M., et al. “Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.” Science, vol. 371, no. 6532, Feb. 2021, pp. 926-931. https://doi.org/10.1126/science.abf4058.

Publisher

American Association for the Advancement of Science (AAAS)

Journal

Science

scimago Q1

wos Q1

SJR

10.416

CiteScore

48.4

Impact factor

45.8

ISSN

00368075 (Print)

10959203 (Electronic)

Profiles